Melinda Wenner Moyer (@Lindy2350) is a science writer based in New York’s Hudson Valley. She is a visiting scholar at NYU’s Arthur L. Carter Journalism Institute and an Alicia Patterson fellow. Moyer writes a column for Slate and is a contributing editor at Scientific American. Her work has also appeared in the New York Times, Mother Jones, and a number of women’s magazines.
Melinda Wenner Moyer
From this contributor
When autistic people commit sexual crimes
Many first-time sex offenders on the spectrum may not understand the laws they break. How should their crimes be treated?
When autistic people commit sexual crimes
By
Melinda Wenner Moyer
17 July 2019 | 19 min read
How pregnancy may shape a child’s autism
Autism is predominantly genetic in origin, but a growing list of prenatal exposures for mother and baby may sway the odds.
How pregnancy may shape a child’s autism
By
Melinda Wenner Moyer
5 December 2018 | 17 min read
Explore more from The Transmitter
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
Supported by a $40 million NIH grant, Yale brain shuttle technology raises questions
Yale University claims its STEP platform might be able to deliver gene-editing tools into the brain via multiple routes. Researchers are eager to see more.
By
Natalia Mesa
3 June 2026 | 11 min read
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
What counts as a ‘naturalistic’ behavior?
Nedah Nemati explains how neuroscience methods and the lived experience of the scientists themselves shape how we define the behaviors we seek to explain.
By
Paul Middlebrooks
3 June 2026 | 1 min read
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
Allen Institute sets sights on treatments for five brain diseases
The Brain Health Accelerator program aims to harness single-cell transcriptomics and cell-type-specific genetic tools to develop treatments for Alzheimer’s, Huntington’s and Parkinson’s diseases, Lewy body dementia and ALS.
By
Calli McMurray
2 June 2026 | 5 min read